Orlando, Florida 32806


A first in human phase 1 study in healthy volunteers and Granulin mutation causative of frontotemporal dementia to assess AL001 safety, tolerability, pharmacokinetics, and pharmacodynamics

Study summary:

This is a first-in-human Phase 1 study designed to investigate the safety, tolerability, PK and PD of intravenously administered AL001 in Healthy Volunteers and asymptomatic FTD-GRN mutation carriers.


Inclusion Criteria: - BMI 18.0-35.0 kg/m2 - 45-120 kg, inclusive - At screening, females must be non-pregnant and non-lactating, or of nonchildbearing potential (either surgically sterilized or physiologically incapable of becoming pregnant, or at least 1-year postmenopausal (amenorrhoea duration of 12 consecutive months); nonpregnancy will be confirmed for all females by a pregnancy test conducted at screening, (each) admission, and at follow-up. - Female participants of child-bearing potential must agree to use adequate contraception from screening until 90 days after the follow-up visit. A - In good physical health on the basis of no clinically significant findings from medical history, physical examination (PE), laboratory tests, 12 lead ECG, and vital signs, as judged by the Investigator. - Willingness and able to comply with the study protocol, in the investigator's judgement. Exclusion Criteria: - Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins. - Positive drug or alcohol at screening and prior to first dose - History of alcohol abuse or substance abuse



Primary Contact:

Principal Investigator
George Stoica
Bioclinica Research

Study Lead
Phone: 4152315660 ext. 328
Email: info@alector.com

Backup Contact:


Location Contact:

Orlando, Florida 32806
United States

Study Coordinator
Phone: 407-841-0502
Email: info@bioclinicaresearch.com

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: February 04, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.